Novartis And GlaxoSmithKline In Multi-Billion Dollar Deals

Mani

Published onApril 22, 2014

Updated on May 13, 2021

Novartis AG (NYSE:NVS) (VTX:NOVN) will acquire GlaxoSmithKline plc (ADR) (NYSE:GSK) (LON:GSK)’s oncology unit for around $14.5 billion, while Glaxo will pay $5.25 billion for Novartis’ vaccines business.

The deal comes on the heels of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) revealing plans to acquire the wrinkle treatment maker Allergan Inc.

Deal to enhance firms’ core focus

While unveiling its fourth quarter earnings in

This content is exclusively for paying members of Hedge Fund Alpha

Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha

Don’t have an account?

Subscribe now and get 7 days free!

This article is only available for Premium Members

Subscribe today and get :
Insider Strategies and Letters to Shareholders from the Top Hedge Funds
Exclusive Access to coverage of Private, Closed-Door Investor Conferences
Hedge Fund Manager Research Currently Producing 21% – 40% Returns Annually

Don’t have an account?

Subscribe now and get 7 days free!

Mani

Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports

Novartis And GlaxoSmithKline In Multi-Billion Dollar Deals

Deal to enhance firms’ core focus

This content is exclusively for paying members of Hedge Fund Alpha

Don’t have an account?

Don’t have an account?

More News

These Funds Were In Leon Cooperman’s Crosshairs

Jonathon Jacobson Invested Over $400 Million Into These Funds

Up 29 Percent YTD, This Fund Is Avoiding Mega-Cap Tech and Winning with Hedges

Alluvial Capital Management 2Q24 Commentary: This Solid $400M Market Cap Real Estate Stock Is Very Cheap And Has A Catalyst

Novartis And GlaxoSmithKline In Multi-Billion Dollar Deals

Deal to enhance firms’ core focus

This content is exclusively for paying members of Hedge Fund Alpha

Don’t have an account?

Don’t have an account?

More News

These Funds Were In Leon Cooperman’s Crosshairs

Jonathon Jacobson Invested Over $400 Million Into These Funds

Up 29 Percent YTD, This Fund Is Avoiding Mega-Cap Tech and Winning with Hedges

Alluvial Capital Management 2Q24 Commentary: This Solid $400M Market Cap Real Estate Stock Is Very Cheap And Has A Catalyst

Get Your Business News